1. Home
  2. PANW vs NVO Comparison

PANW vs NVO Comparison

Compare PANW & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Palo Alto Networks Inc.

PANW

Palo Alto Networks Inc.

HOLD

Current Price

$279.62

Market Cap

212.3B

Sector

Technology

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$43.88

Market Cap

197.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PANW
NVO
Founded
2005
1923
Country
United States
Denmark
Employees
N/A
69500
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
212.3B
197.4B
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
PANW
NVO
Price
$279.62
$43.88
Analyst Decision
Buy
Hold
Analyst Count
39
11
Target Price
$216.28
$51.00
AVG Volume (30 Days)
8.6M
11.3M
Earning Date
05-19-2026
05-06-2026
Dividend Yield
N/A
3.19%
EPS Growth
N/A
N/A
EPS
0.79
N/A
Revenue
$2,273,100,000.00
N/A
Revenue This Year
$24.93
N/A
Revenue Next Year
$19.97
$3.70
P/E Ratio
$353.61
$13.60
Revenue Growth
29.04
N/A
52 Week Low
$139.57
$35.12
52 Week High
$302.95
$71.80

Technical Indicators

Market Signals
Indicator
PANW
NVO
Relative Strength Index (RSI) 64.31 52.92
Support Level $179.81 $43.35
Resistance Level $302.95 $46.05
Average True Range (ATR) 13.67 1.37
MACD -2.91 -0.18
Stochastic Oscillator 58.79 61.34

Price Performance

Historical Comparison
PANW
NVO

About PANW Palo Alto Networks Inc.

Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: